Press releases
Press Releases
IFFIm increases its most recent bond by US$ 250 million to total US$ 1 billion
The US$ 250 million increase will bring the total size of the April 2026 bond to US$ 1 billion.The proceeds will provide US$ 250 million in additional funding for Gavi’s core immunisation programmes and the Gavi COVAX Advance Market Commitment (AMC).London, 18 November 2021 – IFFIm today increased by US$ 250 million the 1% 5-year vaccine bond it is...
Monique Barbut, Hassatou N’Sele and Ingrid van Wees to join IFFIm Board of Directors
New board members bring diverse backgrounds in global development and finance London, 1 July 2021 – IFFIm, the International Finance Facility for Immunisation, has appointed three new global development and finance executives to its Board of Directors. Monique Barbut, President of World Wildlife Fund (WWF) France, Hassatou Diop N’Sele, Trea...
IFFIm Returns to Market with US$ 750 Million 5-year Oversubscribed Vaccine Bonds
IFFIm today priced US$ 750 million, 5-year fixed rate Vaccine Bonds that will provide Gavi, the Vaccine Alliance with immediately available funding to support routine immunisation in lower-income countries. The issuance, which is IFFIm’s second largest ever, will also accelerate the availability of critical funding for the Gavi COVAX Advance Market...
Italy reaffirms support of Gavi and CEPI with €5 million grant to IFFIm
Italy’s new grant will provide immediate funding for CEPI’s COVID-19 vaccine research and development programme.
IFFIm Appoints Kenneth Lay as Chair of its Board of Directors
Lay succeeds Cyrus Ardalan, who introduced CEPI programme and led successful replenishment raising over US$ 926 million.
IFFIm Prices US$500 Million 3-year Benchmark Vaccine Bonds
IFFIm today priced US$ 500 million, 3-year fixed rate benchmark Vaccine Bonds that will provide Gavi, the Vaccine Alliance, flexible funding for its core immunisation programmes and efforts to develop and distribute eventual COVID-19 vaccines to countries around the world, particularly the poorest.
IFFIm issues NOK 2 billion in Vaccine Bonds for COVID-19 vaccine development
IFFIm has issued NOK 2 billion in Vaccine Bonds to accelerate the availability of financing for urgent COVID-19 vaccine research and development by the Coalition for Epidemic Preparedness Innovations.
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.